The 19 CRCT
teams

T2i : Anti-tumour immunity and immunotherapy

Maya AYYOUB, Jean-Pierre DELORD
and 16 collaborators

Deciphering the molecular and cellular mechanisms of tumour sensitivity/resistance to immunotherapy in order to design combined therapies capable of overcoming resistance.

MELASPHINX : Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy

Bruno SEGUI, Nathalie ANDRIEU
and 21 collaborators

Targeting the metabolism of ceramide and its derivatives to prevent tumour progression and overcome resistance to anti-cancer drugs, cytokines and immune cells.

MICROPANC : Microenvironnement and Therapeutic Resistance in Pancreatic Neoplasms

Corinne BOUSQUET
and 18 collaborators

To understand how the tumour microenvironment, and more specifically cancer-associated fibroblast populations, contribute to the heterogeneity of pancreatic tumours and organise their resistance to therapies, in order to propose combinations of drugs that co-target this microenvironment in addition to targeting tumour cells.

NoLymIT : New Immunotherapies Against Lymphoma

Camille LAURENT
and 21 collaborators

Through the study of the immune component of the microenvironment in B lymphoma and Chronic Lymphocytic Leukemia (CLL), the team aims to characterize immune escape mechanisms as well as new therapeutic targets using single-cell sequencing techniques implemented with innovative bioinformatics tools, sophisticated in vitro culture imaging techniques and 3D modeling.

RADOPT : Optimising radiotherapy: from molecular signalling pathways to clinical trials

Elizabeth Cohen-Jonathan Moyal
and 22 collaborators

To optimise radiotherapy in the management of patients with glioblastoma (GBM):  The studies carried out concern the biological mechanisms of radioresistance, the optimisation of the definition of the target to be irradiated and the delivery of the dose on complex volumes in order to decipher the mechanisms of radioresistance, to validate targets of interest to be targeted by specific inhibitors which are then evaluated in clinical trials combining via artificial intelligence approaches all the multi-data of clinical parameters, biological markers, imaging and physics in the prediction of the therapeutic response studied.

GENIM : Genomic and Immunology of myeloma

Hervé AVET-LOISEAU, Ludovic MARTINET
and 24 collaborators

This team is fully dedicated to the understanding and therapeutic targeting of multiple myeloma, an incurable hematological malignancy affecting the bone marrow. More specifically, our team aims to study the impact of genomic and immune factors on the development of myeloma and the response to treatment.

IGAALD : Impact of genetic alterations on acute leukemia development

Eric Delabesse
and18 collaborators

The activity of this team is part of a translational research thanks to a hospital component that allows, in addition to diagnosis, to search for molecular causes (mutations) in patients suffering from leukemia, and a basic research component that models these causes in cells or in mouse models in order to find new therapeutic targets.

METAML : Metabolism and Therapeutic Resistance In Acute Myeloid Leukemia

Jean-Emmanuel SARRY / Carine JOFFRE
and 31 collaborators

Acute myeloid leukaemias are characterised by a high relapse rate in response to treatments, due to the development of resistance to therapies. The aim of the METAML team is to study the mechanisms of adaptation and metabolic reprogramming underlying this resistance in order to develop new therapeutic strategies to eradicate resistant leukaemia cells and prevent relapse.

DynAct : Molecular dynamics of Lymphocyte Interactions

Salvatore VALITUTTI
and 13 collaborators

To use experimental and computational tools to decipher intercellular communication at the immunological synapse between cells of the human immune system in order to better understand immune responses in cancer patients and, in perspective, to contribute to the improvement of immunotherapeutic strategies against cancer

ADAPTAML : Non-genetic adaptive mechanisms and therapy resistance in acute myeloid leukemia

Carine JOFFRE et Margherita GHISI
and 18 collaborators

Acute myeloid leukemia is a highly aggressive and poor prognosis blood cancer that derives from the accumulation of genetic and epigenetic alterations in hematopoietic progenitor cells. Despite important advances in our understanding of this disease, the vast majority of patients experience disease relapse upon therapy and the 5-year survival rate is only 30%. A deeper mechanistic understanding of AML biology alongside the identification of new molecular and cellular vulnerabilities will be key in order to identify new therapeutic strategies and improve patient outcome.